New study explores best guselkumab dose for psoriasis in chinese patients
NCT ID NCT07532486
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares the effectiveness and safety of different doses and schedules of guselkumab in 400 Chinese adults with moderate to severe plaque psoriasis. Participants will receive either a high dose, an extended-interval dose, or the standard dose. The goal is to find the best way to control psoriasis symptoms over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new gel calm psoriasis Flare-Ups?
- Can a Once-Daily cream tame psoriasis in toddlers?
- Can a switch to guselkumab clear stubborn psoriasis?
- Can a new biologic clear stubborn psoriasis?
- Diet and exercise may tame psoriasis in kids — a trial puts it to the test
- Ancient herbal mix put to the test against psoriasis